Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial.
Zhang S, Deshpande A, Verma BK, Wang H, Mi H, Yuan L, Ho WJ, Jaffee EM, Zhu Q, Anders RA, Yarchoan M, Kagohara LT, Fertig EJ, Popel AS. Zhang S, et al. Among authors: yuan l. bioRxiv [Preprint]. 2023 Aug 15:2023.08.11.553000. doi: 10.1101/2023.08.11.553000. bioRxiv. 2023. PMID: 37645761 Free PMC article. Preprint.
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Zhang S, et al. Among authors: yuan l. bioRxiv [Preprint]. 2023 Jan 12:2023.01.10.523481. doi: 10.1101/2023.01.10.523481. bioRxiv. 2023. Update in: Genome Med. 2023 Sep 18;15(1):72. doi: 10.1186/s13073-023-01218-y PMID: 36712023 Free PMC article. Updated. Preprint.
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Zhang S, et al. Among authors: yuan l. Genome Med. 2023 Sep 18;15(1):72. doi: 10.1186/s13073-023-01218-y. Genome Med. 2023. PMID: 37723590 Free PMC article.
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, McDermott DF, Stephen Hodi F, Choueiri TK, Freeman GJ. Mahoney KM, et al. Among authors: yuan l. J Immunother Cancer. 2022 Feb;10(2):e003527. doi: 10.1136/jitc-2021-003527. J Immunother Cancer. 2022. PMID: 35131863 Free PMC article.
A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.
Bu MT, Yuan L, Klee AN, Freeman GJ. Bu MT, et al. Among authors: yuan l. Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):202-209. doi: 10.1089/mab.2021.0068. Epub 2022 Aug 4. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 35925787 Free PMC article.
10,130 results
You have reached the last available page of results. Please see the User Guide for more information.